^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Published date:
    10/25/2022
    Excerpt:
    In irinotecan-refractory patients, cetuximab–irinotecan is recommended over cetuximab alone [II, B].
    Secondary therapy:
    irinotecan
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Colorectal cancer: CONTINUUM OF CARE - SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE...Patient appropriate for intensive therapy...Initial therapy...FOLFOX + (cetuximab or panitumumab)...FOLFIRI + (cetuximab or panitumumab)...or (cetuximab or panitumumab)...SUBSEQUENT THERAPY...Irinotecan (cetuximab or panitumumab)
    Secondary therapy:
    FOLFOX; FOLFIRI; irinotecan